Healthcare Providers and Services
Company Overview of Fox Chase Cancer Center
Fox Chase Cancer Center owns and operates a cancer care hospital in Philadelphia. It offers surgery, radiation oncology, virtual colonoscopy, diagnostic imaging, and breast imaging center of excellence seal services; and develops various therapies and technologies for treating cancer. The company also provides breast evaluation, risk assessment, and cancer education services; and conducts basic, translational, and clinical research with special programs in cancer prevention, detection, survivorship, and community outreach. In addition, it offers fellowship training in breast cancer, hematology, pathology, surgical oncology, advanced minimally invasive thoracic surgery, and urologic oncology....
333 Cottman Avenue
Philadelphia, PA 19111-2497
Founded in 1904
Key Executives for Fox Chase Cancer Center
Chief Executive Officer, President and Cancer Center Director
President of Friends of The Hospital
President of Fox Chase Chapter
Compensation as of Fiscal Year 2016.
Fox Chase Cancer Center Key Developments
Fox Chase Cancer Center Signs an Agreement with Universal Hospital in Abu Dhabi to Design Program Services for a Bone Marrow Transplant Program
Feb 19 16
Fox Chase Cancer Center signed an agreement with Universal Hospital in Abu Dhabi to design program services for a bone marrow transplant program Universal plans to establish within the United Arab Emirates. The agreement is a follow-up to a memorandum of understanding, outlining plans for the hospitals to collaborate on projects, the two organizations signed in November. As part of the partnership, Universal Hospital plans to establish exchange programs and customized physician programs at Fox Chase's affiliated hospitals in the Philadelphia region.
Fox Chase Report Earnings Results for the Year Ended June 30, 2015
Sep 25 15
Fox Chase reported earnings results for the year ended June 30, 2015. For the year, the company had an operating profit of $11.3 million in the year ended June 30 compared to an $18.5 million operating loss the year before.
Horizon Pharma plc Announces Collaboration with Fox Chase Cancer Center to Study ACTIMMUNE (interferon Gamma 1b) in Combination with PD-1/PD-L1 Inhibitors in Various Forms of Cancer
Jul 27 15
Horizon Pharma plc announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma. Preclinical cell line research has indicated that interferon gamma enhances cellular PD-L1 expression on endothelial cells (inner lining of the blood vessel) and on some tumor cells. By enhancing cellular PD-L1 expression on tumor cells, interferon gamma may promote or enhance the effect of the PD-1 or PD-L1 inhibitors. The first study being planned as part of the collaboration will be a dose-ranging study to determine a suitable dose for ACTIMMUNE with PD-1/PD-L1 inhibition. Once the ideal combination strategy is determined, the investigators intend to expand the study to include patients with metastatic bladder and renal cell carcinomas. Additional studies are expected to follow depending on initial results.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|